17022-31-0

Basic information

• Product Name: ETHYL 2-PROPYLPENTANOATE
• Synonyms: ETHYL 2-PROPYLPENTANOATE;valproic acid ethyl ester;Ethyl dipropylacetate;Ethyl valproate;Pentanoic acid, 2-propyl-, ethyl ester
• CAS NO: 17022-31-0
• Molecular Formula: C₁₀H₂₀O₂
• Molecular Weight: 172.26
• Mol File: 17022-31-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 195.7°Cat760mmHg
• Flash Point: 71.4°C
• Appearance: /
• Density: 0.872g/cm³
• Vapor Pressure: 0.413mmHg at 25°C
• Refractive Index: 1.421
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: ETHYL 2-PROPYLPENTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-PROPYLPENTANOATE(17022-31-0)
• EPA Substance Registry System: ETHYL 2-PROPYLPENTANOATE(17022-31-0)

Safety Data

• Hazardous Substances Data: 17022-31-0(Hazardous Substances Data)

Usage

Uses

Valproic Acid Ethyl Ester is the ethyl ester derivative of one of the major antiepileptic drugs, Valproic Acid (V094750). It has potential to be used as a biofuel, has a pleasant odor, and displays marked resistance to clouding and crystallization.

InChI:InChI=1/C10H20O2/c1-4-7-9(8-5-2)10(11)12-6-3/h9H,4-8H2,1-3H3

Upstream product

• 64-17-5 ethanol 
• 99-66-1 valproic acid 
• 2936-08-5 valproyl chloride 
• 60-29-7 diethyl ether 
• 6065-63-0 2,2-dipropyl-malonic acid diethyl ester 
• 539-82-2 ethyl n-valerate 
• 106-94-5 propyl bromide 
• 76002-02-3 ethyl 2-acetyl-2-propylpentanoate 

Downstream Products

• 130201-23-9 1,1-Bis(4'-brombiphenyl-3-yl)-2-propyl-1-pentanol 
• 1069-66-5 sodium valproate 
• 690988-44-4 ethyl 4-(2-propylpentanamido)benzoate 
• 2936-08-5 valproyl chloride 
• 130201-25-1 1,1-Bis(4'-brombiphenyl-3-yl)-2-propyl-1-penten 
• 99-66-1 valproic acid 

Relevant articles and documents

Enantio- and Regioselective Palladium(II)-Catalyzed Dioxygenation of (Aza-)Alkenols

An oxidative Pd-catalyzed intra-intermolecular dioxygenation of (aza-)alkenols has been reported, with total regioselectivity. To study the stereoselectivity, different chiral ligands as well as different hypervalent-iodine compounds have been compared. I

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.